FC-12738
/ Neurodegenerative Disease Research
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 27, 2025
Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Neurodegenerative Disease Research Inc | Recruiting ➔ Completed
Trial completion
February 21, 2024
Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Neurodegenerative Disease Research Inc | Not yet recruiting ➔ Recruiting
Enrollment open • IL6 • TNFA
August 07, 2023
Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Neurodegenerative Disease Research Inc
New P1 trial
1 to 3
Of
3
Go to page
1